![]() In vitro, expanded hfNPCs retained neural features, multipotency, and self-renewal, which supported the development of a cell banking strategy. We now conducted a similar study of human-fetal-spinal-cord-derived NPCs (hfNPCs) from legal gestational interruptions at the late gestational stage, at 19–21.6 weeks. We previously demonstrated that NPCs derived from rat fetal spinal cords primed with a polyglutamate (PGA)-conjugated form of the Rho/Rock inhibitor fasudil (PGA-SS-FAS) displayed enhanced neuronal differentiation and graft survival when compared to non-primed NPCs. Depending on the cell source, additional limitations to NPC-based therapies include high tumorigenic potential, alongside poor graft survival and engraftment into host spinal tissue. Neural precursor cell (NPC) transplantation represents a promising therapy for treating spinal cord injuries (SCIs) however, despite successful results obtained in preclinical models, the clinical translation of this approach remains challenging due, in part, to the lack of consensus on an optimal cell source for human neuronal cells. Authors may use MDPI'sĮnglish editing service prior to publication or during author revisions. ![]() Submitted papers should be well formatted and use good English. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Please visit the Instructions for Authors page before submitting a manuscript. Cells is an international peer-reviewed open access semimonthly journal published by MDPI. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. All manuscripts are thoroughly refereed through a single-blind peer-review process. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). ![]() For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Research articles, review articles as well as short communications are invited. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. All submissions that pass pre-check are peer-reviewed. Manuscripts can be submitted until the deadline. Once you are registered, click here to go to the submission form. Manuscripts should be submitted online at by registering and logging in to this website. ![]() This Topical Collection aims to summarize the current knowledge on the beneficial role of stem cells in neural regeneration and functional recovery in spinal cord injury. Moreover, the identification of the regenerative capacity of transplanted stem cells and their use in restorative therapies has led to an alternative approach of recruiting endogenous neural stem cells resident in the injured spinal cord. Several promising trials evaluating the effect of transplanting a variety of stem cells or stem cell-derived cells in various spinal cord injury models have yielded promising results. Emerging trends utilizing cell replacement strategies have been pursued with the hopes of providing restorative targets to make new connections and/or remyelinate damaged axons. Various regenerative strategies to facilitate functional recovery after SCI have been explored with the goal of promoting axonal regeneration and myelination. The pathophysiological events that occur after the primary spinal cord injury serve to create an environment that impairs axonal regrowth and recovery. Loss of motor and/or sensory function is a sequalae of both the primary spinal cord insult and a cascade of secondary events that include inflammation, neuronal cell death and formation of a glial scar. Spinal cord injury is a devastating complication of trauma that often results in various degrees of neurological compromise.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |